Crimson Merger Sub II

POINT Biopharma is a biopharmaceutical company specializing in the development of precision radioligand therapies for cancer treatment. The company's pipeline is led by PNT2002, a PSMA-targeted radiopharmaceutical in Phase 3 development for metastatic castration-resistant prostate cancer, and PNT2003, which targets somatostatin receptors for neuroendocrine tumors. POINT distinguishes itself through a vertically integrated supply chain and a purpose-built radiopharmaceutical manufacturing facility designed to ensure reliable isotope delivery. In December 2023, the company was acquired by Eli Lilly and Company for approximately $1.4 billion. This acquisition integrated POINT's radioligand platform and clinical assets into Lilly's oncology division. The company continues to advance its pipeline of alpha and beta-emitting radioisotopes to address various solid tumor indications.